Palbociclib After CDK and Endocrine Therapy (PACE)

Palbociclib After CDK and Endocrine Therapy (PACE)

Conditions: Metastatic Breast Cancer
Interventions: Drug: Palbociclib; Drug: Fulvestrant; Drug: Avelumab
Sponsors: Dana-Farber Cancer Institute; Pfizer
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 13, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments